IPP Bureau
GABIT acquires Swedish nutrition brand Nack to build integrated longevity ecosystem
By IPP Bureau - December 21, 2025
Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch
By IPP Bureau - December 21, 2025
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays
By IPP Bureau - December 21, 2025
The initiative is focused on a problem that continues to plague cancer outcomes in India
BPL Medical Technologies funds AI dept at Sri S Ramasamy Naidu Memorial College
By IPP Bureau - December 21, 2025
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
Gut health crisis fuelling anxiety, early ageing & lifestyle diseases
By IPP Bureau - December 21, 2025
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
Bristol Myers Squibb to provide Eliquis free to Medicaid
By IPP Bureau - December 21, 2025
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
Merck strikes historic deal with Trump admin to lower drug costs for Americans
By IPP Bureau - December 21, 2025
Takeda posts strong Phase 3 win for oral psoriasis drug
By IPP Bureau - December 21, 2025
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease
By IPP Bureau - December 21, 2025
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
Qihan Biotech launches first-in-human trial of off-the-shelf CAR-T therapy for refractory lupus
By IPP Bureau - December 21, 2025
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease
By IPP Bureau - December 20, 2025
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
Briefs: APL Healthcare, Biocon, USFDA, Sun Pharma and Clean Fino-Chem
By IPP Bureau - December 20, 2025
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Cosette Pharmaceuticals launches first generic CIPRO HC with 180 Days market exclusivity
By IPP Bureau - December 20, 2025
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year
By IPP Bureau - December 20, 2025
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery
By IPP Bureau - December 20, 2025
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
